– USA, MA – Entrada Therapeutics, Inc., a biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointment of Mary Thistle to its Board of Directors.
“We are delighted to welcome Mary to Entrada,” commented Board Chairman, Kush Parmar. “Her extensive industry experience will help ensure the Board effectively supports the Company’s long-term strategy.”
“Mary is a recognized leader in the biotechnology industry and has a remarkable track record,” said CEO, Dipal Doshi. “We look forward to having Mary’s counsel as we leverage our recent $116 million Series B financing to expand our pipeline and aim to bring new and needed treatment options to patients living with devastating diseases.”
About Mary Thistle
Mary Thistle currently serves as Special Advisor at the Bill & Melinda Gates Medical Research Institute. She has more than 25 years of experience in finance, strategy, and business development across a range of therapeutic areas, including a deep background in rare diseases.
Ms. Thistle serves on the Board of Directors of Homology Medicines, Enterome SA, and Ziopharm Oncology.
Before joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle was COO of Dimension Therapeutics. At Dimension, she oversaw the company’s Series B financing and initial public offering, expanded the pipeline through strategic business development transactions, and led the sale of the company to Ultragenyx. Before joining Dimension, Ms. Thistle was SVP, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. She has also held senior-level positions at ViaCell in finance, operations, and business development and then served as SVP, Business Development at PerkinElmer after ViaCell was acquired. Ms. Thistle began her career in finance as a Certified Public Accountant.
“Entrada’s Endosomal Escape Vehicle platform represents a significant advancement in the field of intracellular biologics,” said Ms. Thistle. “The team’s research has the potential to address a wide range of diseases and therapeutic areas, and I’m excited to be able to contribute to Entrada’s mission.”
About Entrada Therapeutics
Entrada Therapeutics’ mission is to transform the treatment of devastating diseases and improve patients’ quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein, and peptide programs to efficiently target and engage underlying drivers of diseases. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics.
For more information: https://www.entradatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.